3 unprofitable stocks that make us think twice

Unprofitable companies face headwinds as they struggle to control operating costs. Some may invest heavily, but the majority fail to translate spending into sustainable growth.

A lack of profit can lead to problems, but StockStory will help you identify the companies that have a chance to survive. With that in mind, here are three unprofitable companies that won’t make it, and some better opportunities instead.

GAAP operating margin over 12 months: -2.2%

Founded in 1895, Albany (NYSE:AIN) is a global textile and materials processing company specializing in machine clothing for paper mills and composite structures for the aerospace and other industries.

Why do we avoid AIN?

1. Annual sales growth of 1.5% over the past two years was slower than in the industrial sector

2. The 10.7 percentage point decline in free cash flow margin over the past five years reflects the company’s increased investments to defend its market position

3. Diminishing returns on capital from an already weak starting point show that management’s past investment decisions and current situation are ineffective

Albany trades at $57.90 per share, or 23.7x forward price-to-earnings ratio. Read our free research report and find out why you should think twice about including AIN in your portfolio: it’s free.

GAAP operating margin over 12 months: -1.141%

Strategy (NASDAQ:MSTR), once a traditional business intelligence software provider, is developing AI-powered business analytics software while functioning as a major corporate holder of Bitcoin cryptocurrency.

Why is MSTR risky?

1. MicroStrategy’s core analytics software is overshadowed by its all-in Bitcoin strategy, leaving product innovation and business deals hungry for attention

2. The Company’s Debt-Financed Bitcoin Purchases Tie Shareholder Fortunes to Crypto Fluctuations and Interest Rates, Increasing Downside Risk and Uncertainty

3. On the plus side, the massive Bitcoin treasury gives executive chairman Michael Saylor a unique springboard to capture crypto upside and court investors looking for exposure to digital assets.

Strategy is trading at $134.85 per share at a forward price-to-sales of 76.4x. To learn more about why MSTR doesn’t meet our standards, check out our free in-depth research report.

GAAP operating margin over 12 months: -8.7%

With a diverse portfolio of eight FDA-approved medications targeting neurological disorders, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders, including epilepsy, ADHD, Parkinson’s disease and migraines.

Why are we careful with SUPN?

1. Annual revenue growth of 5.6% over the past five years was below our healthcare industry standards

2. Its $717.2 million revenue base puts the company at a disadvantage against larger competitors that exhibit economies of scale

3. Free cash flow margin fell 14.4 percentage points over the past five years, implying the company became more capital intensive as competition increased

Supernus Pharmaceuticals’ share price of $49.90 implies a valuation ratio of 21.5x forward price-to-earnings ratio. If you’re considering SUPN for your portfolio, check out our FREE research report to learn more.

ONE MORE THING: Top 6 stocks for this week. This market quickly separates quality stocks from expensive stocks. AI is taking down entire industries without warning. With such a rapid rotation, you need more than a list of good companies.

Our AI system flagged Palantir before it hit 1,662%. AppLovin before it was running 753%. Nvidia before it turned 1.178%. Every week it produces 6 new names that pass the same tests. Receive our top 6 stocks for free HERE.

The stocks that made our list in 2020 include now household names like Nvidia (+1.326% between June 2020 and June 2025) and under-the-radar companies like the once microcap company Tecnoglass (+1.754% over five years). Find your next big winner today with StockStory.